Colorectal cancer genetic screening

Contact details:
Bristol Genetics Laboratory
Pathology Sciences
Southmead Hospital
Bristol, BS10 5NB
Enquiries: 0117 414 6168
FAX: 0117 414 6464

Head of Department:
Professor Rachel Butler, FRCPath
Consultant Clinical Scientist

Consultant Lead for Rare Disease:
Maggie Williams, FRCPath

Consultant Lead for Oncology:
Christopher Wragg, FRCPath

Service Lead:
Claire Faulkner PhD
Claire.Faulkner@nbt.nhs.uk

Sample Required
Paraffin embedded tumour tissue
- >20% tumour: 5 x 10µm sections in a clean universal
- <20% tumour: 10 x 5µm slide mounted sections along with H&E with regions of >20% tumour highlighted

If available, a normal tissue block or blood sample (5ml EDTA) to be sent to aid analysis.

Samples should be accompanied by a FULLY completed Molecular Pathology request form (available from the laboratory or www.nbt.nhs.uk/genetics)

All samples should be labelled with patient name, date of birth and pathology block number

Consent and Storage:
All genetic testing requires consent. It is the responsibility of the referring clinician to ensure that appropriate consent has been obtained.

DNA is stored from ALL patients undergoing DNA testing, unless consent for this is specifically denied.

Stored material from all referrals may be retained for quality assurance purposes and may be used anonymously for the development of new tests for the disorder in question.

Clinical Background and Genetics
MSI (microsatellite instability) occurs in 10-20% of patients with a diagnosis of colorectal cancer. MSI may be detected using molecular / genetic analysis or immunohistochemistry of the mismatch repair genes. The detection of MSI determines:
(a) That stage II patients should not be treated with chemotherapy, as they are unlikely to respond.
(b) Patients are more likely to respond to immunotherapy.
(c) Tumours should be further tested for the BRAF p.V600E mutation and MLH1 promoter methylation to determine if the tumour is sporadic or associated with Lynch syndrome.

Lynch syndrome accounts for 3-6% of colorectal cancer (CRC) and is associated with mutations in the mismatch repair (MMR) genes (MLH1, MSH2, MSH6 and PMS2). A screening test for tumour microsatellite instability (MSI) is helpful in targeting families suitable for MMR gene testing, as MSI-High status increases the likelihood that a MMR mutation will be detected.

BRAF p.V600E mutation testing and MLH1 promoter methylation testing also assists in stratification as the presence of both in an MSI-High tumour is suggestive of a tumour of sporadic origin.

Service Offered
- Microsatellite instability is detected using the MSI Analysis System, Version 1.2 (MD1641 Promega).

If MMR IHC has already been performed (and shows loss of protein), it is acceptable to send samples for BRAF / MLH1 methylation analysis alone

- The c.1799T>A p.(Val600Glu) mutation in BRAF is detected by pyrosequencing. This assay can detect 5% p.(Val600Glu) in a background of wildtype DNA.

- MLH1 promoter hypermethylation testing is carried out by methylation specific pyrosequencing.

Referrals
- Referrals are accepted from Clinical Genetics, Oncologists or Histopathology Consultants.
- For sample requirements please refer to the information on the left.

Clinical Advice
If clinical discussion is required, we would recommend contact with Dr Newton Wong, Consultant Histopathologist, Southmead Hospital.

Target Reporting Times
- MSI testing to inform treatment: 14 days
- MSI testing (+/- BRAF/MLH1) for Lynch pre-screening: 28 days
- BRAF/MLH1: 14 days

Quality
BGL participates in the GENQA scheme for this service.

References